ImmunoFyx is a private early-stage biotechnology company focused on novel antibody fusion proteins targeting highly metastatic solid tumours. Up to 90% of cancer deaths are associated with metastases for which there are few treatment options. ImmunoFyx utilizes unique combinations of endogenous anti-cancer proteins to reduce tumour growth, angiogenesis and metastases.
Our partner BioTalent Canada has launched the Building Workplace Resiliency resources for its I.D.E.A.L. Biosciences Employer Recognition Program. This program served as a guide for employers seeking to submit fall program applications.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.
member